Valuation: CSL Limited

Market Cap 38.25B 33.6B 31.24B 28.67B 53.87B 3,684B 54.7B 371B 145B 1,811B 144B 141B 6,262B P/E 2026 *
-42.4x
P/E 2027 * 26.6x
Enterprise Value 46.98B 41.26B 38.37B 35.21B 66.16B 4,524B 67.18B 456B 178B 2,224B 176B 173B 7,690B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.97x
Free-Float
99.3%
Yield 2026 *
3.57%
Yield 2027 * 3.65%
1 day-1.32%
1 week-6.34%
Current month-0.45%
1 month+1.95%
3 months-11.46%
6 months-36.41%
Current year-33.84%
1 week 113.75
Extreme 113.75
124.64
1 month 112.4
Extreme 112.4
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%-6.34%-56.98%-57.24% 38.64B
+1.86%-1.72%+17.78%-8.54% 66.32B
+1.23%+2.80%+37.51%+202.14% 52.6B
+10.08%+51.80%+51.80%+51.80% 43.27B
+0.75%-1.65%+52.79%-26.86% 29.62B
+1.38%+0.84%+67.73%+86.31% 23.31B
-4.19%-11.57%+60.75%-55.56% 22.62B
-1.21%-4.51%+2.22%+174.24% 20.22B
-0.22%-0.95%+61.97%+123.78% 16.29B
+2.13%+4.13%+85.59%+154.93% 16.26B
Average +1.05%-0.87%+38.11%+64.50% 32.92B
Weighted average by Cap. +1.64%-0.45%+30.85%+55.03%

Financials

2026 *2027 *
Net sales 15.37B 13.5B 12.56B 11.52B 21.65B 1,480B 21.98B 149B 58.25B 728B 57.71B 56.47B 2,516B 15.58B 13.68B 12.72B 11.67B 21.94B 1,500B 22.27B 151B 59.03B 737B 58.47B 57.21B 2,550B
Net income -974M -856M -796M -730M -1.37B -93.81B -1.39B -9.45B -3.69B -46.12B -3.66B -3.58B -159B 1.19B 1.04B 970M 890M 1.67B 114B 1.7B 11.51B 4.5B 56.2B 4.46B 4.36B 194B
Net Debt 8.73B 7.66B 7.13B 6.54B 12.29B 840B 12.48B 84.64B 33.07B 413B 32.76B 32.05B 1,429B 7.99B 7.02B 6.53B 5.99B 11.26B 770B 11.43B 77.52B 30.29B 378B 30B 29.36B 1,308B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-24 A$114.22 -1.32% 1,114,296
26-07-23 A$115.75 -1.86% 1,250,961
26-07-22 A$117.94 -2.83% 1,089,586
26-07-21 A$121.38 -1.00% 892,794
26-07-20 A$122.61 -0.58% 672,117
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
79.62USD
Average target price
96.99USD
Spread / Average Target
+21.81%

Quarterly revenue - Rate of surprise